SCM
TSHA icon

Superstring Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Superstring Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-258,269
Closed -$1.15M – 40
2026
Q1 		$1.15M Sell
258,269
-722,499
-74% -$3.36M 0.82% 28
2025
Q4 		$5.39M Buy
+980,768
New +$4.76M 2.89% 11
2025
Q2 		– Sell
-755,599
Closed -$1.05M – 47
2025
Q1 		$1.05M Buy
+755,599
New +$1.26M 1.25% 22

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Superstring Capital Management's TSHA Position: Q2 2026 in Review

Superstring Capital Management sold out of Taysha Gene Therapies (TSHA) in Q2 2026, closing a stake of 258,269 shares — an estimated $1.15M sold.

Superstring Capital Management first reported a position in TSHA in Q1 2025 and held it in 3 quarters. The position peaked at $5.39M in Q4 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Superstring Capital Management reported no remaining Taysha Gene Therapies position as of Q2 2026 after selling out during the quarter.
  • Superstring Capital Management sold 258,269 Taysha Gene Therapies shares in Q2 2026, an estimated $1.15M.
  • Superstring Capital Management first reported a position in Taysha Gene Therapies in Q1 2025 and held it in 3 quarters.
  • Superstring Capital Management's Taysha Gene Therapies position peaked at $5.39M in Q4 2025.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Superstring Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.